User profiles for "author:Richard Simon"

Richard Simon

R Simon Consulting, Formerly Chief, Computational & Systems Biology, National Cancer …
Verified email at mail.nih.gov
Cited by 93356

Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification

R Simon, MD Radmacher, K Dobbin… - Journal of the …, 2003 - academic.oup.com
DNA microarrays have made it possible to estimate the level of expression of thousands of
genes for a sample of cells. Although biomedical investigators have been quick to adopt this …

Cystic fibrosis adult care: consensus conference report

JR Yankaskas, BC Marshall, B Sufian, RH Simon… - Chest, 2004 - journal.chestnet.org
Abbreviations: ADA Americans with Disabilities Act; BMD bone mineral density; BMI body
mass index; CBAVD congenital bilateral absence of the vas deferens; CF cystic fibrosis; CFF …

Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting

A Dupuy, RM Simon - Journal of the National Cancer Institute, 2007 - academic.oup.com
Background Both the validity and the reproducibility of microarray-based clinical research
have been challenged. There is a need for critical review of the statistical analysis and …

[HTML][HTML] The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

A Rosenwald, G Wright, WC Chan… - … England Journal of …, 2002 - Mass Medical Soc
Background The survival of patients with diffuse large-B-cell lymphoma after chemotherapy
is influenced by molecular features of the tumors. We used the gene-expression profiles of …

[HTML][HTML] Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells

SS Dave, G Wright, B Tan, A Rosenwald… - … England Journal of …, 2004 - Mass Medical Soc
Background Patients with follicular lymphoma may survive for periods of less than 1 year to
more than 20 years after diagnosis. We used gene-expression profiles of tumor-biopsy …

Optimal two-stage designs for phase II clinical trials

R Simon - Controlled clinical trials, 1989 - Elsevier
The primary objective of a phase II clinical trial of a new drug or regimen is to determine
whether it has sufficient biological activity against the disease under study to warrant more …

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

A Rosenwald, G Wright, K Leroy, X Yu… - The Journal of …, 2003 - rupress.org
Using current diagnostic criteria, primary mediastinal B cell lymphoma (PMBL) cannot be
distinguished from other types of diffuse large B cell lymphoma (DLBCL) reliably. We used …

Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial

SJ Pocock, R Simon - Biometrics, 1975 - JSTOR
In controlled clinical trials there are usually several prognostic factors known or thought to
influence the patient's ability to respond to treatment. Therefore, the method of sequential …

Molecular classification of cutaneous malignant melanoma by gene expression profiling

M Bittner, P Meltzer, Y Chen, Y Jiang, E Seftor… - Nature, 2000 - nature.com
The most common human cancers are malignant neoplasms of the skin,. Incidence of
cutaneous melanoma is rising especially steeply, with minimal progress in non-surgical …

Flexible regression models with cubic splines

S Durrleman, R Simon - Statistics in medicine, 1989 - Wiley Online Library
We describe the use of cubic splines in regression models to represent the relationship
between the response variable and a vector of covariates. This simple method can help …